1. In Vivo

Will AI Obviate The Need For Animal Trials?

 
• By David Wild

Quris-AI has built a platform that can simulate genetically diverse clinical trials on a chip. The technology may reduce biopharma’s need for animal testing and de-risk human testing. 

Bio Bytes
• Source: Shutterstock

Israeli-American biotech Quris-AI’s platform can test thousands of drug candidates on hundreds of miniaturized and genetically diverse collections of organs-on-a-chip, effectively creating a “clinical-trial-on-a-chip.” The robust AI-based approach predicts drug toxicity with a level of accuracy that won it a partnership with Merck KGaA.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By David Wild

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years

 
• By Andrew Warmington

As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

 
• By Jo Shorthouse

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.